WO2024150177 - TREATMENT METHODS FOR SOLID TUMORS
National phase entry is expected:
Publication Number
WO/2024/150177
Publication Date
18.07.2024
International Application No.
PCT/IB2024/050305
International Filing Date
11.01.2024
Title **
[English]
TREATMENT METHODS FOR SOLID TUMORS
[French]
MÉTHODES DE TRAITEMENT DE TUMEURS SOLIDES
Applicants **
ADVESYA
ETABLISSEMENT FRANÇAIS DU SANG
Inventors
RAFIK, Haberbache
WARDA, Walid
DESCHAMPS, Marina
FERRAND, Christophe
Priority Data
63/479,471
11.01.2023
US
63/599,189
15.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2499 | |
| EPO | Filing, Examination, Granting | 11437 | |
| Japan | Filing, Examination, Granting | 2296 | |
| South Korea | Filing, Examination, Granting | 2315 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
23,887
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure provides methods of treating a solid tumor in a subject comprising administration of a cell comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antigen-binding fragment thereof that binds IL-1RAP, a transmembrane domain, and an intracellular signaling domain comprising at least a stimulatory domain.[French]
L'invention concerne des méthodes de traitement d'une tumeur solide chez un sujet, consistant à administrer une cellule comprenant une molécule d'acide nucléique codant pour un récepteur antigénique chimérique (CAR), le CAR comprenant un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie à IL-1RAP, un domaine transmembranaire, et un domaine de signalisation intracellulaire comprenant au moins un domaine de stimulation.